Upstream Bio (UPB) Fundamental Analysis: Revenue, Earnings & Valuation

5.50 / 10

Netural

Fundamental assessment yields a 5.5/10 score, indicating average quality. Revenue‑to‑MV and Cash‑to‑MV are modestly positive, inventory turnover is strong, but fixed‑asset turnover and income‑tax‑to‑profit ratios are weak. PB‑ROE is low, suggesting limited valuation upside.

Analysis Checks(7/10)

Revenue-MV

Value-5.35

Score2/3

Weight18.69%

1M Return8.45%

Total operating revenue (YoY growth rate %)

Value20.42

Score2/3

Weight-1.84%

1M Return-1.06%

Inventory turnover ratio

Value103.94

Score3/3

Weight15.23%

1M Return6.74%

Gross profit margin (%)

Value100.00

Score2/3

Weight3.47%

1M Return1.69%

PB-ROE

Value1.51

Score1/3

Weight12.76%

1M Return5.29%

Income tax / Total profit (%)

Value21.05

Score1/3

Weight-0.88%

1M Return-0.50%

Fixed assets turnover ratio

Value1.38

Score1/3

Weight-2.12%

1M Return-1.24%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight8.81%

1M Return4.32%

Asset-MV

Value-0.49

Score3/3

Weight32.34%

1M Return11.84%

Cash-MV

Value-0.09

Score2/3

Weight13.53%

1M Return5.94%

Is UPB fundamentally strong?

UPB scores 5.50/10 on fundamentals and holds a Fair valuation at present. Backed by its -35.43% ROE, -5026.03% net margin, -3.53 P/E ratio, 1.49 P/B ratio, and 52.33% earnings growth, these metrics solidify its Netural investment rating.